Dopavision careers

Our goal is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific
photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Bundesministerium für
Bildung und Forschung/German Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.